Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annexon, Inc.ANNX · Entity 5011 | CHIEF MEDICAL OFFICER | March 02, 2026 | March 04, 2026 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | Chief Medical Officer | March 31, 2023 | April 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annexon, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,582 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 5,820 · Balance 123,582 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: This transaction was executed in multiple trades in prices ranging from $5.36 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2: This transaction was executed in multiple trades in prices ranging from $5.36 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Unity Biotechnology, Inc.
Report date March 31, 2023 · Filed April 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 62,817 |
Reported balance
After 2023-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-31 · Sale · Disposed 420 · Balance 62,817 F1: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2: Includes Restricted Stock Units which vest over time measured from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
F2: Includes Restricted Stock Units which vest over time measured from the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 21:30 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 5,820 | $5.43 | $31,602.60 |
DisclosureSEC source: 0001734424-26-000003 · form4-03042026_040342.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,582 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $5.36 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 00:09 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001734424-26-000002 · form4-02242026_120253.xml · derivative · entry 2 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2036-02-19 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 00:09 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 56,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001734424-26-000002 · form4-02242026_120253.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,402 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:30 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 5,290 | $5.10 | $26,979.00 |
DisclosureSEC source: 0001734424-26-000001 · form4-02202026_040203.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,152 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $4.93 to $5.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:55 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 228,225 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001415889-25-006195 · form4-03032025_090331.xml · derivative · entry 2 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,225 Underlying: Common Stock · 228,225 shares Expires 2034-02-27 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 27, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:54 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 5,521 | $2.96 | $16,342.16 |
DisclosureSEC source: 0001415889-25-004891 · form4-02202025_090205.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,479 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $2.855 to $3.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Mar 3, 2025 21:55 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 44,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006195 · form4-03032025_090331.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,442 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 27 of each year, with the first 1/3rd vesting on February 27, 2026. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:32 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001415889-24-004627 · form4-02212024_040231.xml · derivative · entry 2 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-02-16 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 16, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:32 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004627 · form4-02212024_040231.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 16 of each year, with the first 1/3rd vesting on February 16, 2025. Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 21:07 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001610717-23-000220 · form4.xml · derivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from July 27, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 16:51 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 420 | $1.70 | $714.00 |
DisclosureSEC source: 0000899243-23-010235 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,817 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 17:02 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 1,005 | $4.00 | $4,020.00 |
DisclosureSEC source: 0000899243-23-008588 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,237 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:33 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 863 | $4.84 | $4,176.92 |
DisclosureSEC source: 0000899243-23-003870 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,242 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 16:44 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 1,016 | $2.85 | $2,895.60 |
DisclosureSEC source: 0000899243-22-038614 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,105 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. F3 · balance_after: Reflects a 1-for-10 reverse stock split of the Issuer's common stock, effected by the Issuer on October 19, 2022, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 17:35 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000899243-22-036543 · doc4.xml · derivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-11-18 F1 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on February 18, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 16:10 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 10,923 | $0.48 | $5,243.04 |
DisclosureSEC source: 0000899243-22-031139 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,213 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 18:11 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 4,398 | $0.59 | $2,594.82 |
DisclosureSEC source: 0000899243-22-024439 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,136 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 16:49 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 3,697 | $0.62 | $2,292.14 |
DisclosureSEC source: 0000899243-22-023584 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,534 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 16:34 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 10,530 | $0.63 | $6,633.90 |
DisclosureSEC source: 0000899243-22-022587 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,231 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 16:24 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 4,188 | $1.14 | $4,774.32 |
DisclosureSEC source: 0000899243-22-013110 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,761 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant dat Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 16:53 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 10,581 | $0.88 | $9,311.28 |
DisclosureSEC source: 0000899243-22-011062 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,949 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| February 09, 2022 Filed Feb 15, 2022 17:23 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 183,333 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000899243-22-006454 · doc4.xml · derivative · entry 2 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,333 Underlying: Common Stock · 183,333 shares Expires 2032-02-09 F3 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| February 09, 2022 Filed Feb 15, 2022 17:23 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 45,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006454 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,530 F1 · shares: Represents Restricted Stock Units ("RSUs") one third of which vests on February 9, 2023 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes RSUs which vest over time measured from the grant date. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 16:26 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 10,614 | $1.63 | $17,300.82 |
DisclosureSEC source: 0000899243-21-048359 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,697 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 17:16 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0000899243-21-026228 · doc4.xml · derivative · entry 2 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-23 F3 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 17:16 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026228 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,875 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from June 24, 2021. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes RSUs which vest over time measured from the grant date. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 17:03 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 3,515 | $4.18 | $14,692.70 |
DisclosureSEC source: 0000899243-21-025521 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,875 F1 · kind: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 17:13 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 2,829 | $5.73 | $16,210.17 |
DisclosureSEC source: 0000899243-21-014349 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,390 F1 · kind: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| March 30, 2021 Filed Oct 1, 2021 21:57 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 40,564 | $2.95 | $119,663.80 |
DisclosureSEC source: 0000899243-21-038737 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,311 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| September 13, 2020 Filed Sep 15, 2020 21:01 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025182 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,219 F1 · shares: Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F1 · balance_after: Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes RSUs which vest over time measured from the grant date. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 16:59 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 2,483 | $9.67 | $24,010.61 |
DisclosureSEC source: 0000899243-20-017554 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,219 F1 · kind: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 17:08 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 98,490 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0000899243-20-009846 · doc4.xml · derivative · entry 2 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,490 Underlying: Common Stock · 98,490 shares Expires 2030-03-29 F3 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 17:08 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 24,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-009846 · doc4.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,702 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from March 30, 2020. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes RSUs which vest over time measured from the grant date. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 16:17 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 106,800 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013882 · doc1.xml · derivative · entry 2 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,800 Underlying: Common Stock · 106,800 shares Expires 2029-06-19 F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 48 successive, equal monthly installments measured from June 20, 2019, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 16:17 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock | 21,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013882 · doc1.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,447 F1 · shares: RSUs which vest 1/3 annually over 3 years measured from June 20, 2019. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:20 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries C Preferred Stock · Derivative | 1,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022044 · doc1.xml · derivative · entry 4 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,630 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:20 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries B Preferred Stock · Derivative | 74,048 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022044 · doc1.xml · derivative · entry 3 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,048 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:20 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 1,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022044 · doc1.xml · nonDerivative · entry 2 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:20 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 74,048 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022044 · doc1.xml · nonDerivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| May 02, 2018 Filed May 4, 2018 18:20 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 30,508 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001140361-18-021811 · doc1.xml · derivative · entry 1 Dananberg Jamie · CIK 0001734424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,508 Underlying: Common Stock · 30,508 shares Expires 2028-05-01 F1 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on the one-year anniversary of May 2, 2018, and 1/48th of the shares shall vest on each monthly anniversary thereafter, subject to the optionee remainining a service provider to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.